Direct Impact of In-House Rapid Lung Next-Generation Sequencing on Outcomes for Patients with Cancer - European Medical Journal

Direct Impact of In-House Rapid Lung Next-Generation Sequencing on Outcomes for Patients with Cancer

Oncology

This webinar was supported by Thermo Fisher.

Our latest webinar explores precision oncology in the form of biomarkers and treatments for non-small cell lung cancer. Francesco Passiglia, Thoracic Oncologist, San Luigi Hospital, Orbassano, Turin, Italy, and Associate Professor in the Department of Oncology at the University of Turin, Italy, present on turnaround time as a barrier to precision treatment plans, and spotlight how rapid lung next-generation sequencing can combat this.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.